Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
U.S. Clinician and Payer Receptivity to Immune Checkpoint Inhibitors in Oncology | Physician & Payer Forum | US | 2015
Ushering in a New Era of Cancer Immunotherapies in NSCLC, Malignant Melanoma, Renal Cell Carcinoma, and SCCHN The field of cancer immunotherapy has witnessed considerable advances over the past few…
The Burgeoning Prostate Cancer Market in the EU5 | Physician & Payer Forum | EU5 | 2015
Five premium-priced therapies – Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare), Zytiga (Janssen), and Jevtana (Sanofi) – are approved in Europe…
EU5 Market Access Opportunities and Barriers for Outpatient Parenteral Antibiotic Therapy| Physician & Payer Forum | EU5 | 2015
Outpatient parenteral antimicrobial therapy (OPAT) is a convenient mechanism for treating patients with infections that require intravenous (IV) antibiotic drugs but are clinically stable and do…
Location Location Location: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic Device Industry
Patients surgically treated for orthopedic indications have a unique set of characteristics when compared with other surgical patients; critically, surgical treatment for these patients is often…
Opportunities and Challenges in the Japanese Pharmaceutical and Regenerative Medicine Market
With a series of recent advancements in pharmaceutical market access, Japan is transforming into a market where companies with innovative products can benefit from more opportunities. In addition,…
